Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 1;160(6):674-676.
doi: 10.1001/jamadermatol.2024.0403.

Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

William Mark Richardson  1 , Jill T Shah  1 , Daniel R Mazori  1 , Avrom S Caplan  1 , Kristen I Lo Sicco  1 , Alisa N Femia  1
Affiliations

Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

William Mark Richardson et al. JAMA Dermatol. .
No abstract available

Plain language summary

This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Ms Shah reported receiving a grant from the National Center for Advancing Translational Sciences, National Institutes of Health, during the conduct of the study. Dr Lo Sicco reported serving as a consultant for Aquis and Pfizer. Dr Femia reported receiving consulting fees from Octagon Therapeutics, Timber Pharmaceuticals, and Guidepoint. No other disclosures were reported.

Similar articles

See all similar articles

References

    1. Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339-353. doi:10.1007/s40257-020-00502-6 - DOI - PubMed
    1. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25-34. doi:10.1016/j.jaad.2010.09.016 - DOI - PMC - PubMed
    1. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken). 2015;67(5):667-672. doi:10.1002/acr.22498 - DOI - PMC - PubMed
    1. Hodgkinson LM, Wu TT, Fiorentino DF. Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med. 2021;9(5):433. doi:10.21037/atm-20-5175 - DOI - PMC - PubMed
    1. Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352. doi:10.3389/fimmu.2021.773352 - DOI - PMC - PubMed

Substances